Skip to main content
. 2012 Oct;28(10):1285–1293. doi: 10.1089/aid.2011.0142

Table 3.

Prevalence of the K65R Mutation in Patients Failing Highly Active Antiretroviral Therapy According to HIV-1 Subtype and Treatment

 
 
 
 
 
 
p valueb
NRTI-treated patients at GRT with C AG F p valuea B C vs. B AG vs. B F vs. B
Exp to ddI or TDF or ABC or d4T 21 18 26   405      
Therapy duration,c weeks, median (IQR) 68 (33–100) 47 (33–74) 67 (26–127)   68 (40–104)      
K65R prevalence, N (%) 4 (19.0) 0 (0.0) 0 (0.0) 0.03 17 (4.2) 0.01    
Exp to ddI or TDF or ABC, but no exp to d4T 17 8 22   141      
Therapy duration,c weeks, median (IQR) 57 (17–109) 37 (23–51) 27 (24–92)   49 (26–78)      
K65R prevalence, N (%) 1 (5.9) 0 (0.0) 0 (0.0)   6 (4.2)      
Exp to d4T, but no exp to ddI or TDF or ABC 2 3 3   28      
Therapy duration,c weeks, median (IQR) 72 (44–100) 42 (29–54) 77 (54–104)   73 (37–109)      
K65R prevalence, N (%) 1 (50.0) 0 (0.0) 0 (0.0)   1 (3.6)      
a

Differences in the prevalence of K65R among the three non-B subtypes were assessed by the Chi square test (2×3 table).

b

Differences in the prevalence of K65R between non-B subtypes and the B subtype were assessed by the Fisher exact test.

c

Therapy duration indicates the total weeks under ddI, TDF, d4T, or ABC treatment.

The prevalence of the K65R mutation was calculated in groups of patients treated with NRTI and with a similar median therapy duration at the moment of the genotypic resistance test. Only significant p values (p<0.05) are reported in the table.

ABC, abacavir; AG, CRF02_AG; d4T, stavudine; ddI, didanosine; Exp, experience; GRT, genotypic resistance test; NRTI, nucleoside reverse transcriptase inhibitors; TDF, tenofovir.